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A P P L I E D  S C I E N C E S  A N D  E N G I N E E R I N G
Electronics with shape actuation for minimally  
invasive spinal cord stimulation
Ben J. Woodington1†, Vincenzo F. Curto1†, Yi-Lin Yu2,3, Héctor Martínez-Domínguez4, 
Lawrence Coles1, George G. Malliaras1*, Christopher M. Proctor1*‡, Damiano G. Barone1,2*‡ 
Spinal cord stimulation is one of the oldest and most established neuromodulation therapies. However, today, 
clinicians need to choose between bulky paddle-type devices, requiring invasive surgery under general anesthetic, 
and percutaneous lead–type devices, which can be implanted via simple needle puncture under local anesthetic 
but offer clinical drawbacks when compared with paddle devices. By applying photo- and soft lithography fabri-
cation, we have developed a device that features thin, flexible electronics and integrated fluidic channels. This 
device can be rolled up into the shape of a standard percutaneous needle then implanted on the site of interest 
before being expanded in situ, unfurling into its paddle-type conformation. The device and implantation proce-
dure have been validated in vitro and on human cadaver models. This device paves the way for shape-changing 
bioelectronic devices that offer a large footprint for sensing or stimulation but are implanted in patients percuta-
neously in a minimally invasive fashion.
INTRODUCTION
Spinal cord stimulation (SCS) is one of the most established neuro-
modulation therapies in clinical use. As of 2018, SCS devices were 
one of the most commonly used interventional neuromodulation 
techniques, with approximately 50,000 devices implanted annually 
(1). The first use of SCS was for the treatment of pain conditions, 
notably intractable back pain, but is now used to treat pain located 
in the legs, back, and chest, e.g., angina (2). It is estimated by the 
Centers for Disease Control and Prevention that, today, up to 8% of 
the U.S. population suffer from intractable back pain, that is, debil-
itating pain that is not responding to treatment by conventional 
methods such as nonsteroidal anti-inflammatory drugs or opioid 
drugs. SCS has now been used for several decades; however, despite 
its proven efficacy, cost-effectiveness, and advantages offered over 
conventional drug-based therapy, it remains neglected as a treat-
ment by many general practitioners (3).
Patients undergoing SCS therapy will have electrodes implanted 
into the epidural space of the spinal column. The electrodes are usu-
ally connected to an implanted pulse generator, which controls the 
stimulation parameters. SCS devices are commonly separated into 
two categories: percutaneous linear-type probes and paddle-type 
probes, consisting of a one-dimensional (1D) and a 2D array of 
electrodes, respectively (4). With less than a 2-mm diameter, the 
cylindrical, linear design can be implanted percutaneously via a Tuohy 
needle in a relatively low-risk and simple “day surgery” procedure 
(5). Unfortunately, the benefit of simple implantation is negated by 
its decreased capability to manage pain because of its limited spatial 
range and likelihood of migration (displacement) when compared 
with a paddle-type probe (6). Implantation of up to three linear 
probes is possible to cover a larger area but generally remains less 
effective and more likely to migrate during its lifetime compared 
with a paddle-type device (7). Moreover, a linear electrode produces 
a spherical electric field of which only the part aimed toward the 
spinal cord is effective, leading to a reduced energy efficiency and 
limiting the capacity for a more targeted therapy (8).
Conversely, a paddle electrode, which is typically as wide as 
12 mm, produces an electric field that is oriented toward the spinal 
cord only; thus, less power is required to obtain similar results (3). 
The array of forward-facing electrodes also allows for improved, 
more predictable targeting of electrical stimulation and a higher 
number of electrodes per device, typically between 16 and 32 (9). 
The flexibility in electrode configuration and the fixed relative posi-
tion of the electrodes are likely the reasons these devices are com-
monly used in clinical investigations beyond the treatment of pain 
(10, 11). The dominant drawback in using a paddle-type electrode is 
that a more invasive, higher-risk surgical procedure is required to 
implant the device (9). More recently, there has been interest within 
academic and clinical groups with regard to applying SCS to pa-
tients with spinal cord injury suffering from full or partial paralysis 
(10, 12–14) or movement disorders within Parkinson’s disease (15).
While patients and carers are faced with a choice between paddle- 
type and percutaneous implants, recent technological developments 
in bioelectronics are changing the paradigm for the fabrication of 
implantable devices: This trend involves the use of techniques of the 
semiconductor industry to develop high-resolution microelectrode 
arrays made of thin films that are ultraconformable and include ca-
pabilities such as microfluidics for drug delivery. Examples include 
cortical arrays for recording brain activity at single neuron resolu-
tion (16) and spinal cord implants that can be used for rehabilitative 
therapy and are softer and more conformable than existing semirigid 
technologies (17, 18). These devices are advancing our understand-
ing of the neural networks (19, 20) and are beginning to be translated 
to the clinic (21). At the same time, the field of soft robotics has 
yielded powerful paradigms of devices where shape is a dynamic 
property that can be changed using, e.g., pneumatic actuation (22–24). 
Devices with integrated fluidic channels are shown to be used as dy-
namic artificial organs and surgical manipulators. Here, we combine 
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these two ideas to develop a minimally invasive paddle-type SCS 
(MI-SCS) comprising thin film electronics and integrated fluidics 
for mechanical actuation. The device can be rolled up to fit into a 
needle, allowing percutaneous implantation during a low-risk sur-
gical procedure, and then expanded in situ to provide a paddle-type 
analog. This capability, transcends the duality of percutaneous 
versus paddle-type implants, offering the best of both worlds. It 
paves the way for implants in which shape is a dynamic property 
that can be manipulated by the clinician to minimize the invasive-
ness of neurosurgery and access high-performance form factors.
RESULTS
Design of the MI-SCS
MI-SCS was designed and fabricated using standard photolithogra-
phy and soft lithography techniques. Components of the device 
intended to make contact with the patient were made entirely from 
biocompatible materials including parylene-C, silicone, polyethylene, 
polyimide, and gold. The MI-SCS functions as a paddle-type device 
analog once implanted, with the electrodes conforming to the sur-
face of the dura but adapts to the dimensions of a percutaneous lead 
device during insertion. This is achieved by designing a fully rolla-
ble device from thin film electronics, which can be inserted via a 
percutaneous needle, and actuated with air pressure once implanted 
to transform into its functional, paddle-like orientation (Fig. 1A).
Once rolled, the device, and all packaging, including fluidic con-
nections, electrical connections, and supporting tubing, was de-
signed to be less than 2 mm in diameter to fit inside 14-gauge Tuohy 
needles, commonly used in percutaneous SCS lead placement. The 
packaging approach relied on concentric tubing, with the entire 
device enclosed in a polyimide tube, called the introducer. This pro-
tects the device as it is inserted into the body as well as assists in the 
navigation and reducing insertion trauma owing to its narrow foot-
print. A second smaller polyethylene tube contains the electronic 
connections and the fluidic tubing. The fluidic tube is the smallest 
and most nested of the tubes, allowing for connection between the 
embedded device fluidics and an external pump or syringe. The flu-
idic tubing acts additionally as a lumen for placement of a rigid stylet. 
During device insertion, a 400-m stylet (Nuvectra, USA) is placed 
inside the fluidic tubing. This gives the device more mechanical stability 
and prevents kinking during insertion, an event that could damage 
the spinal cord or device. Electrical connections are made to the 
device using a custom thin, flexible cable, bonded using an aniso-
tropic conductive film (ACF). The device design is shown in Fig. 1B.
Fabrication of the MI-SCS fluidic was achieved by creating a 
monolithic device using a process of incomplete silicone cure with 
a virtual fluidic created from an antiadhesive spacer. Under this 
method, the base layer of the fluidic does not fully cure before the 
second capping layer is added. Allowing the two layers to co-cure 
this way creates very strong cross-linked bonding, which results in 
a thin, robust device that is not prone to failure under pressure. 
Initially, fabrication of the device fluidics was explored using silicone- 
silicone bonding via O2 plasma activation, a common technique 
used in silicone fabrication (25, 26), but this option does not enable 
the device to hold high-enough internal pressures. The bonding 
surface of the device was more prone to leak when under the 
amount of fluidic pressure required to unfurl the device. This moti-
vated the move to create a monolithic silicone fluidic.
Using the techniques outlined, it was possible to fabricate the 
MI-SCS to a thickness between 30 and 60 m, where device thickness 
Fig. 1. Design and fabrication of the MI-SCS. (A) A conceptual cross section of an implanted device within the spinal cord and a render of the device in its rolled and 
unrolled state within the spinal column. (B) A fabricated MI-SCS device before being packaged with the connections tube and secured inside the introducer. Inset is a 
device render with componentry annotated. (C) A cross-sectional diagram of the MI-SCS device. (D) An exploded illustrative view of the device architecture. (E) An optical 
image of the device wrapped helically around a tube to demonstrate inherent flexibility. (F) An optical image of the device positioned on a tube structure showing the 
representative electrode size. Photo credit: Ben Woodington, University of Cambridge.
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is dominated by the silicone fluidic layer, with the electronic layer at 
only 4 m (Fig. 1, C and D). During the MI-SCS device develop-
ment, it was recognized that x-ray opacity was a key design require-
ment; this led to the placement of x-ray opaque markers, which 
were integrated during the soft lithography step as shown in Fig. 1D; 
these are staggered to allow the implanting clinician to infer the orienta-
tion of the device. Optical images of functional devices are shown in 
Fig. 1 (E and F). Figure 1E shows the intrinsic flexibility of the device 
owing to the thin films of silicone, parylene-C, and gold used for 
fabrication. Additional design and dimensional information is shown 
in fig. S1.
In vitro validation
The devices were investigated in vitro for several features, including 
electrical stability, mechanical robustness, and dimensional changes 
following actuation of the fluidic component. Device unrolling was 
tested in a bench top model designed to simulate the epidural spinal 
cord space (Fig. 2A). The model consisted of a latex balloon inflated 
with water inside of a rigid container, simulating the virtual epidural 
space in  vivo. The devices were inflated by hand using a syringe 
until they unfurled within the model. They were then placed in a 
bath of water, and pressure was added via a manual syringe while 
observing for any air bubbles leaking from the device.
The MI-SCS device was characterized for its electrical properties 
using electrical impedance spectroscopy techniques. First, rolling 
and packaging robustness was observed. The results show no in-
crease in impedance during this rolling/unrolling cycle (Fig.  2B). 
Impedance was also used as an indicator of electrode functionality 
and yield. From the numerous impedance measurements carried 
out, an electrode yield of 80% was calculated.
Device stability for repeated bending was also determined; this 
was to ensure device integrity following a normal range of bending, 
which an implanted device would undergo. The number of sagittal 
plane bending cycles the human spine undergoes is varied but is 
estimated to be around 4400/day (27), the majority of these move-
ments <10° in extent. The 107 bending cycles carried out during this 
work would therefore represent approximately 6 years of mechani-
cal stress in vivo. A gradual increase in impedance can be observed 
for the first 105 cycles, after which the impedance plateaus. After 107 
bending cycles, the impedance remains within the expected range 
of 102 to 103 ohms (Fig. 2C). Charge injection capacity (CIC) limit 
and cathodal charge storage capacity (CSCc) characterization experi-
ments were carried out for the device as shown in Fig. 2 (D and E). 
CIC measurements were carried out using a three-electrode system 
as reported in the literature (28, 29). Voltage transients were ob-
served and recorded using an oscilloscope. Increasing current was 
applied using a stimulation/recording device (Intan) until reaching 
gold water window limits; CIC was reported per unit area. CSCc 
measurements were determined using a three-electrode setup and 
potentiometer. The cathodal portion of the cyclovoltammetry (CV) 
curves was integrated with respect to time to generate charge capacity; 
CSC was reported per unit area.
During early in vitro testing, an important clinical constraint 
was identified. This was the issue of what we have called anterior- 
posterior (AP) device expansion. This is where the device, when 
actuated, balloons out of plane rather than only expanding across its 
planar axis. If uncontrolled, the expansion in the AP dimension 
could put excessive pressure on the spinal cord, causing damage. A 
design restraint was established for the MI-SCS in which any fluidic 
actuation should not cause the device to excessively expand out of 
plane or balloon so that excess pressure is not placed on the spinal 
cord during device deployment. To limit this, pillar-like structures 
were engineered throughout the fluidic. Figure 2F shows the com-
parison between a pillow-like design initially conceived and a de-
vice used during the cadaveric validation of the MI-SCS. These 
expansion data are supported with a finite element model that 
explores device deformation and relative stresses on a device under 
pneumatic pressure using a reference material (figs. S2 and S3) (30).
After finalizing the fluidic design, the fluidic actuation of the de-
vice was assessed for pressure testing in triplicate (Fig. 2G). This is 
to ensure that the device does not fail during actuation in vivo. 
Devices were inflated at 1 ml/min using a syringe pump. Below the 
neck of the syringe, a Y-connector was used, which led to a pneu-
matic pressure sensor (shown in fig. S8). The devices were filled 
until failure, indicated by a sudden drop-off in pressure as shown in 
Fig. 2B. MI-SCS devices were able to hold between 8 to 12 kPa of 
pressure before failing.
Human cadaveric validation
After successful in vitro validation, human cadaveric models were 
used to test the proposed surgical approach of fully packaged MI-
SCS devices. A spinal cord model was established by reconstituting 
the subdural space with saline. A fluidic tube was secured within the 
spinal cord, and a flow pump was used to perfuse the spinal cord 
with constant pressure. This was to reduce the epidural space and 
simulate a clinically relevant environment. Figure 3A shows how, 
immediately following exposure, the spinal cord is dehydrated, and 
a large epidural space remains (left). Following stable perfusion, the 
spinal cord appears brighter and wider (right), and the epidural 
space is reduced to an anatomically representative size.
The devices were implanted at the L3/4 vertebra (Fig. 3B) by a 
trained neurosurgeon operating as close to a percutaneous device 
implantation procedure as was possible, i.e., through a Tuohy nee-
dle, without performing a laminectomy at the device insertion site. 
Each device was then connected to a syringe (Fig. 3C) ready to be 
actuated using air by the operator.
MI-SCS devices enclosed within a polyimide introducer tube 
were inserted through a 14-gauge Tuohy needle and navigated up 
the spinal column (S3), centrally, on the posterior side of the spinal 
cord (Fig. 3D). Once in location, as indicated by fluoroscopy, they 
were deployed onto the dura (Fig. 3E). Device unrolling was vali-
dated by fluoroscopy imaging initially, although some devices were 
validated using a liquid, iodine-based radio-opaque contrast agent 
(Fig. 3F). Although this did not offer a perfectly clear image via 
fluoroscopy, an optimized method could be considered in the future. 
Last, a full spinal cord laminectomy was performed at the site of 
implantation (Fig. 3G).
DISCUSSION
In this work, we have leveraged developments in thin film bio-
electronics and soft robotics to demonstrate a flexible, shape-changing, 
paddle-type spinal cord stimulator that can be inserted percutane-
ously. Our approach involves active, on-demand shape actuation 
and represents a paradigm change to previously reported passive 
shape-changing materials or injectable devices. We show that it is 
possible to introduce such a device to a human cadaver using stan-
dard percutaneous procedures and expand the device into its 
Woodington et al., Sci. Adv. 2021; 7 : eabg7833     25 June 2021
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
4 of 8
paddle conformation in a clinically relevant location on the spinal 
cord. When deployed, the device expands to the dimension of com-
mon, clinically available paddle SCS devices, with a width as large as 
14 mm. This is comparable to the popular Medtronic 5-6-5 device, 
which has a width of 12 mm, while potentially offering far fewer 
surgical risks and a day surgery procedure, which would involve a 
simple epidural needle insertion.
The limitations of x-ray imaging proved to be a challenge in the 
placement of thin film bioelectronic devices guided by fluoroscopy. 
Several techniques and materials were explored to improve the 
opacity of the device under fluoroscopy. Our strategy to solve this is 
the incorporation of bismuth microparticles into a silicone matrix, 
which we mold into markers. These devices can be seen under fluo-
roscopy following standard U.K. radiography practices. The inherent 
softness of silicone allows for the device to be packaged within the 
introducer tube, a small sub-2-mm space. Patterning with this 
material could be explored in the future to further aid device inser-
tion and positioning.
Device robustness, yield, and functionality were of crucial inter-
est for this work. Device failures did present themselves; however, 
this was overwhelmingly due to fluidic failure as opposed to electri-
cal failure. As the devices required relatively high pressure to be 
manipulated in vivo, any pinholes or tears in the silicone chamber 
would result in nonfunctional devices. We aim to optimize this pro-
cess to improve on device yield and consistency in the future.
The validation of this device concept was carried out on human 
cadaver models. The intention behind this was to validate the 
underlying mode of operation for the device and to test its mechanical 
Fig. 2. In vitro assessment of the device design. (A) Time series of an MI-SCS device being tested in an in vitro model to check for actuation and investigate whether air 
leaks are present. This model consisted of a latex balloon (Durex, UK) inflated with water inside of a secondary rigid container. Devices were actuated manually using a 
syringe. (B) Impedance recordings (1 kHz) from the MI-SCS (n = 9) before (preroll) and after (postroll) rolling and packaging the device inside of the introducer tubing. 
(C) Impedance reported at 1 kHz for MI-SCS device electrodes (n = 7) following a logarithmic increase in bending cycles. (D) A representative cyclovoltammetry (CV) re-
cording from the device electrode A spread of the calculated cathodal charge storage capacity (CSCc) across three devices and eight electrodes is shown (n = 8). (E) A repre-
sentative voltage transient charge injection curve is shown for the device electrode. A spread of calculated charge injection capacity (CIC) is shown for 11 electrodes 
across 3 devices (n = 11). (F) Image of a device showing maximum pneumatic expansion with a pillow-like fluidic structure (bottom) and a device with pillar-like structures 
engineered throughout the fluidic (top). The fluidic design is shown inset. (G) Time series graph of MI-SCS devices being inflated with air pressure at constant flow via a 
syringe pump until failure, as indicated by the sudden drop-off in pressure. Photo credit: Ben Woodington, University of Cambridge.
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capability. Furthermore, spinal cord stimulators with electrodes of 
similar dimension have been long accepted as offering clinical 
benefits to patients suffering from pain conditions. Hence, in vivo 
animal testing was not justified at this stage of development. Owing 
to the relative size of the device, being designed for human treat-
ment, and difficulties in scaling the device to very small sizes suit-
able for murine models, large-mammal models would need to be 
used to carry out further validation. In future work, we aim to carry 
out these experiments to further demonstrate the safety profile of 
this device, its utility in treating pain, and the long-term chronic 
acceptance of such a device.
Here, we have shown that by combining photo- and soft lithog-
raphy fabrication methods, we can create a clinically relevant 
paddle-type SCS device with the advantages of being thin and flex-
ible enough to be implanted through minimally invasive means. 
Although we have applied the device to a spinal cord stimulator 
matching commonly used dimensions of existing paddle-type de-
vices, we envisage a device that could cover a much larger area while 
retaining a small insertion footprint, offering a new paradigm for 
central nervous system interfaces. Devices leveraging this kind of 
shape-changing fluidic actuation in situ could be applied to other 
stimulating or recording devices where low-risk surgery is preferred, 
such as on the brain or retina or in hard-to-reach parts of the body, 
for example, deep peripheral nerves or organ interfaces. Using this 
shape-adaptive technology, we will be able to place large-area elec-
trical interfaces throughout the body using only low-risk, keyhole- 
like, and minimally invasive surgical approaches. In addition to 
shape change, the combination of bioelectronics and soft robotics 
can yield implants with unique properties such as self-motility in-
side the body, revolutionizing the way we practice neurosurgery.
MATERIALS AND METHODS
Study design
The hypothesis behind this study was that by integrating fluidic 
channels into thin, flexible electronic devices, we could create a new 
class of neuromodulation device. This device could be implanted 
through a small surgical site, i.e., a needle channel, and actively ex-
panded by a clinician into a large-area electronic device at the site of 
interest. With SCS as the target indication, we sought to combine 
the advantages of both percutaneous lead– and paddle-type devices 
currently clinically available.
Fig. 3. Human cadaveric assessment of the device and surgical procedure. (A) The spinal reconstitution procedure: The image on the left is how the dura is observed 
once exposed on the specimen following a laminectomy. The image on the right shows the surface of the dura following stable reconstitution with saline via the cervical 
spinal cord. (B) An MI-SCS device being placed on the spinal cord via a Tuohy needle with a stylet in place. (C) The stylet is removed, and the MI-SCS fluidic tubing is con-
nected to a syringe, ready for actuation. (D) A fluoroscopy image of the device being guided rostrally along the spinal column. The blue box indicates the Tuohy needle 
location, and the red box highlights the MI-SCS device. (E) A series of fluoroscopy images: on the left, the device has been implanted and positioned but is in its rolled 
state, and on the right, the device has been actuated, as shown by a wider device profile; the darker vertical lines show the position of the fluoroscopy markers. (F) A time 
series of fluoroscopy images from an MI-SCS device inflated with an iodine-based contrast ink from within a human cadaver spinal column. From left (rolled) to right 
(unrolled). (G) A laminectomy and spinal cord exposure being performed once a device had been actuated; this was to directly observe the positioning of the implanted 
device. The main image shows the Tuohy needle at the lower section of the back. The image inset shows a device laying epidurally on the spinal cord. Photo credit: 
Mr. Christopher Constant, Evelyn Cambridge Surgical Training Centre.
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Our first goal was to design these devices and test them within an 
in vitro environment, developing the best form of fluidic actuation 
and optimizing fabrication methodologies to produce a robust de-
vice, thin enough to package inside a standard Tuohy needle.
Our second goal was to test the robustness of these electronics 
undergoing the type of mechanical stresses one would expect during 
the packaging and clinical use of the device throughout its lifetime. 
A secondary aim was to test the failure threshold of the device when 
undergoing inflation.
The third goal was to validate the device in a clinically relevant 
model, notably using human cadavers. Following model develop-
ment, we sought to demonstrate that the device could be implanted 
using standard percutaneous surgical approaches, imaged using 
standard equipment (e.g., fluoroscopy) and actively deployed using 
pneumatic pressure in situ.
Mechanical/electrical characterization was performed for n = 9 
and n = 7 electrodes for packaging and chronic bending testing, re-
spectively. Charge storage and charge injection experiments were 
performed on n = 8 and n = 11 electrodes, respectively, sampled 
across three devices at random. None of the experimental work or 
data analysis was performed blinded.
Fabrication of MI-SCS
A visual representation for the fabrication of the MI-SCS is provided 
in fig. S4. The fluidic portion of the device was created by soft li-
thography forming of silicone (Nusil MED-6015, Polymer Systems 
UK). The base-layer silicone was first diluted with hexane at a 50% 
ratio. The organic solvent was used to reduce the viscosity of the 
uncured silicone (31, 32) before spin coating and resulted in a thin-
ner final device. Spin coating was carried out at 1500 rpm for 90 s to 
form 10-m-thick layers. A 6-m-thick parylene antiadhesive spac-
er was placed following a brief (5 to 10 min) partial curing step at 
60°C to form the fluidic channel. A capping layer of silicone was 
added by blade coating using a 23-m-thick spacer. During the for-
mation of the silicone fluidic, x-ray markers in the form of bismuth 
powder (mesh 100, Sigma-Aldrich, UK)–infused silicone cords 
were integrated along the flanks of the device. The device was then 
treated using a silane solution (A174, Thermo Fisher Scientific, UK) 
and coated with a 1-m-thick parylene-C layer.
The electronics were fabricated from gold using standard photo-
lithographic processing using a plastic photomask (JD Photo Data). 
AZ5214E photoresist (Merck) was spin coated onto the wafers at 
4000 rpm for 30 s. This was followed by a baking step on a hot plate 
at 110°C for 120 s. After the substrates returned to ambient tem-
perature, they were exposed to ultraviolet (UV) (7 s, 80 mJ/cm2) 
using a mask aligner (Karl Suss Contact Mask Aligner MA/BA6), 
and this was followed by a second baking step at 110°C for 120 s. 
The substrates were allowed to cool for several minutes before being 
flood exposed with UV light (20 s, 80 mJ/cm2). The substrates were 
allowed to cool and developed in AZ741 (Merck)/deionized (DI) 
water (1:4) for 38 to 40 s; this was then rinsed with DI water and air 
dried with compressed nitrogen. Each sample was inspected with a 
Zeiss Axio Scope (A1) to ensure complete development.
The substrate was activated with O2 plasma under vacuum (60 s 
at 100 W and 0.6 mbar O2) using a PlasmaPro 80 reactive ion etching 
(RIE). Using a Lesker e-Beam evaporator (PVD 75), titanium (Ti) 
and gold (Au) were deposited to produce the electronic compo-
nents of the device. First, 10-nm Ti was evaporated under vacuum 
(<6 × 10−6 torr). The substrate was allowed to rest under vacuum for 
10 min before 100-nm Au was deposited. Liftoff was performed 
with acetone, the substrates were allowed to soak for 30 min, and 
they were then sprayed with acetone from a bottle to encourage 
the remaining material to be removed. Last, the substrates were 
washed with isopropyl alcohol (IPA) and inspected under an 
optical microscope to ensure complete liftoff. If any traces were 
shorted due to incomplete liftoff, these were further treated with 
acetone.
Following a second parylene deposition, photolithography was 
repeated to expose electrodes and contact pads using AZ9260 
(Merck), spin coated for 3000 rpm for 30 s, and baked at 120°C for 
120  s. They were then UV-exposed for 20  s and developed in 
AZ726MiF (Merck) for 6.5  min. The substrate was then etched 
using RIE [Oxford Plasma Pro 80 RIE, 160 W/O2 50 standard cu-
bic centimeter per minute (sccm)/CHF3 5 sccm] until metal expo-
sure was complete.
The devices were packaged using custom-built polyimide/copper 
flexible cables (Printed Electronics, UK) and a Fintech bonder using 
ACF (Jetro, Japan). The polyethylene fluidic connector tubing 
[Porex 0.4-mm inside diameter (ID)/0.8-mm outer diameter (OD), 
Scientific Laboratory Supplies Ltd, UK] was placed by hand and 
fixed by injecting a small volume of 2-part epoxy resin (RS Pro, UK) 
around the connector. The tip of the tubing was sealed with epoxy 
to ensure the stylet did not pierce the device fluidic during inser-
tion. The tube was perforated with small air holes to allow airflow 
into the fluidic during actuation.
All electrical and fluidic connections were packaged inside a 
connections tubing (Pellathane 55D, Nordson Medical, USA), which 
was sealed with a small amount of epoxy (RS Pro, UK). The entire 
device was then rolled and placed inside the outer introducer tubing 
(Reinforced PI, Nordson Medical, USA). A small amount of silicone 
oil (Nusil MED-450, Polymer Systems, UK) was used to lubricate 
the final introducer packaging step to reduce stress and damage on 
the device. This process is illustrated in fig. S5.
Electrical characterization
To investigate the electrical characteristics of the device, three-point 
impedance measurements were taken before and after expected device 
stresses. Impedance measurements can shed light on whether the elec-
trodes or interconnects are being damaged during these process-
es. All impedance measurements were taken using an AutoLAB 
potentiostat, a phosphate-buffered saline (PBS) solution (0.01 M, 
Sigma- Aldrich), and a platinum electrode was used at the elec-
trode interface.
Impedance measurements were taken on the device before rolling 
into the sheath at nine electrode locations. These devices were then 
rolled into their sheath tubing and actuated to encourage unrolling 
on the bench; the second impedance spectroscopy measurements 
were taken at the sampling sites. Impedance was measured between 
105 and 100 Hz and reported at 1 kHz.
CSC of the device was determined using three-point CV tech-
niques. Measurements were carried out using an AutoLAB potentio-
stat with a PBS solution (0.01 M, Sigma-Aldrich) used as electrolyte. 
A platinum electrode was used as the counter electrode, while an 
Ag/AgCl electrode was used as a reference. CV measurements were 
carried out using a 0.1-V sweep rate and 0.00244-V step within a win-
dow of −0.6 to 0.8 V, the established water window for gold. A minimum 
of six cycles were performed for each measurement to allow the re-
cording to settle, and only the final recorded cycle was analyzed.
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The CIC of the device was determined using a stimulation source 
and measured voltage transients using an oscilloscope. An Intan RHS 
128-channel stim/recording controller and an RHS2000 32-channel 
headstage were used to connect to the device and provide a charge- 
balanced current stimulation pulse with a phase width of 633.3 s 
and an interphase delay of 100 s. Platinum probes were used as 
both counter and reference electrodes, and a PBS solution (0.01 M, 
Sigma-Aldrich) was used as electrolyte. The pulse was gradually in-
creased in amplitude while observing the voltage transient trace 
from a Keysight DSOX1204G oscilloscope. When the cathodic inter-
phase transient reached −0.6 V, the current amplitude was recorded.
As the MI-SCS would be situated on the spinal cord in clinical 
practice, it was necessary to assess the mechanical robustness of the 
device, mainly concerned with the electrodes and/or interconnects 
fracturing. A custom rig was designed and built to hold devices on 
a flexible bed; either end of this bed was attached to a stress/strain 
cycler capable of applying push or pull forces on a device. The push-
pull motion caused a bending in the bed, which bent the device. The 
bed was programmed to implement a full-bend cycle every 2 s to 
varying angles between 5° and 45°. Impedance spectroscopy mea-
surements were taken from seven electrodes of the device, repre-
senting top, middle, and bottom portions of the device, after 0, 102, 
103, 104, 105, 106, and 107 bending cycles. Impedance was measured 
between 105 and 100 Hz and reported at 1 kHz using a platinum 
reference and counter electrode, and a PBS solution (0.01 M, Sigma- 
Aldrich) was used as electrolyte.
Device pressure characterization
MI-SCS devices were connected to a 60-ml syringe pump (KD 
Scientific) via a 3D-printed t-connector, which led to a pneumatic 
pressure sensor (NXP, MXP5100GP), interpreted by an Arduino 
Mega (fig. S8). The syringe pump was programmed to dispense air 
at 1 ml/min. Devices were inflated while the system pressure was 
measured. When a sudden pressure drop was recorded, indicating 
device failure, the testing was stopped.
Establishing cadaveric model
The MI-SCS devices were tested during three separate of human 
cadaver sessions at the Evelyn Surgical Training Center, Cambridge 
(UK). Three fresh-frozen specimens were used—two male and one 
female. The male specimens were used during the first two sessions 
and the fourth session, whereas the female specimen was used 
during the third session. The model was first established. To achieve 
the spinal reconstitution with saline, the dura was first exposed by 
incision above the cervical part of the spinal cord, followed by the 
removal of spinous process and full laminectomy at the C4 to C6 
vertebrae. An incision was made in the dura with a 18-gauge needle; 
a polyethlye tubing (OD = 1.4 mm) was inserted into the incision 
and secured using a purse string suture (Prolene 4-0), and a small 
amount of cyanoacrylate glue (Locktite) was dispensed around the 
tube to ensure an adequate seal. The tubing was connected to a flow 
pump (Flowsteady, model 200). The pump was set to 140 mmHg at 
a rate of 1.5 liters/min. After 30 s, the dura could be seen to expand, 
and after 60  s, liquid could be seen emerging from the epidural 
space, indicating either a leak of the dura or fluid displacement as 
the dura expanded. The pump was reduced to a pressure of 
70 mmHg and 0.5  liter/min. The seal was monitored for around 
30 min before the first implantation to ensure that the seal held, and 
the dura did not leak or expand further.
Device implantation
The devices were implanted through a 14-gauge spinal needle 
(Hamilton, PN:7749-03, Ga14/100 mm), and a reinforced polyethylene 
introducer (Pellathane 65D, Nordson Medical) was used. A stylet 
was used (Nuvectra, USA) to rigidify the device during insertion. 
During device insertion, images were taken laterally by a fluoro-
scope (fig. S7). The devices were guided rostrally along the spinal 
column on the dural surface. Once the device had been navigated to 
an appropriate position, the stylet was removed, the outer intro-
ducer tubing was retracted, and air pressure provided via a manual 
Luer- lock syringe was used to actuate and unfurl the device. During the 
insertion of the device and during actuation, both still and live images 
were recorded using a fluoroscope (Siemens Siremobil compact L) 
operated by a professional radiographer. Images were captured 
between 80 and 88 kV.
Investigation of suitable x-ray strategy and fabrication 
of x-ray markers
Several x-ray opacity markers were explored, with the use of sili-
cone cords infused with bismuth powder being the most effective. 
These various preparations were first screened using a veterinary 
x-ray machine (fig. S6). The materials were placed either freestand-
ing within the machine or below a canine vertebra for contrast. The 
x-ray was operated by a trained veterinary radiographer and used 
within the power boundaries of normal operation. Although not 
analogous to fluoroscopy and through the trunk of a human, the 
veterinary machine allowed the screening of various materials and 
the observation of their relative opacities using a similar technology. 
All bismuth-infused silicones were prepared in-house. These were 
cast using custom molds, which were 3D printed (Asigna UV cured, 
Detax). A 2:1 mixing ratio of bismuth powder (mesh 100, Sigma- 
Aldrich, UK) to polydimethylsiloxane (Dow Corning 184, 10:1) was 
used. The optimal thickness was 450 m, although markers between 
300 and 1000 m were investigated.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/7/26/eabg7833/DC1
View/request a protocol for this paper from Bio-protocol.
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